Pharmaceuticals
ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release caps...
2025-06-16 09:00
2608
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese
MD, proudly announces the successful completion of patient enrollment in the
TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to
evaluate the safety and efficacy of the MagicTouch
2025-06-13 19:59
2371
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 767762...
2025-06-12 21:17
1698
Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing
* 1st production of pharmaceutical grade egg and milk challenge meals * Product portfolio of challenge meals now includes peanut, milk and egg * Innovation pipeline includes development of 'Top 9' allergen products as well as a products suitable from 6 months DEESIDE, Wales, June 12, 2025 /P...
2025-06-12 19:06
1779
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱® ) was...
2025-06-11 11:34
2185
Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy we...
2025-06-10 23:52
2989
Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing
OSAKA, Japan, June 10, 2025 /PRNewswire/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary — a milestone that reflects two decades of dedication to improving health outcomes through high-quality, patient-centered research. Since its founding in 2005 in...
2025-06-10 09:00
1753
BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration
China's influential innovative drug asset cooperation platform NEWARK, Del., June 9, 2025 /PRNewswire/ -- BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSee...
2025-06-09 14:51
1965
Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association
* EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSG...
2025-06-09 14:16
2289
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 7, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated ...
2025-06-07 11:36
3240
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
* Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All": — A subanalysis of the NefIgArd study demonstrates that early tr...
2025-06-06 16:12
2341
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceut...
2025-06-06 14:00
2169
Kelun-Biotech Announces Approximately US$250 Million Placement
CHENGDU, China, June 6, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of t...
2025-06-06 11:04
4206
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
News Summary * Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1 * Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2 * Takes the industry-leading sensitivity of Xevo TQ Absolut...
2025-06-04 08:00
2211
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
MELBOURNE, Australia and KYOTO, Japan, June 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that it has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific re...
2025-06-04 06:30
3797
Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
* EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. * The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of p...
2025-06-03 14:00
2670
International Healthcare Week 2025 - Innovate, Collaborate, And Elevate Healthcare In ASEAN And Beyond
KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ -- International Healthcare Week (IHW) 2025, Southeast Asia's premier healthcare event, will be held from July 16 to 18 at the Malaysia International Trade and Exhibition Centre (MITEC), Kuala Lumpur. Organised by Informa Markets, IHW 2025 is set ...
2025-06-02 10:59
2796
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical iso...
2025-06-02 09:00
2807
Teddy Laboratory (GuanHe Pharmaceuticals) Signs Strategic Cooperation Agreement with LabConnect to Forge a New Landscape in Laboratory Services Collaboration
JOHNSON CITY, Tenn., May 30, 2025 /PRNewswire/ -- Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central laboratory services. The two parties will jointly build a full-chain laboratory service system covering...
2025-05-30 05:05
2243
Dx&Vx Accelerates Development of Universal COVID-19 Vaccine
* Emerging as a next-generation vaccine amidst global resurgence of COVID-19 * Expanding v arious pipelines other than universal COVID vaccine SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Bio-healthcare company Dx&Vx (DXVX) has officially announced the acceleration of its development progr...
2025-05-29 21:03
2163
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 310 media titles]
2026-01-15 13:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 298 media titles]
2026-01-21 12:39JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 296 media titles]
2026-01-15 10:00Infobip strengthens leadership to drive growth and innovation
[Picked up by 281 media titles]
2026-01-16 11:00
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 279 media titles]
2026-01-20 15:40
Most Read
NLCS (Singapore) Brings World-Class Musical Opportunities to Young Artists Across Asia
2026-01-14 07:00
8007
